Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease

Feldman, Gregory; Galkin, Dmitry; Patel, Pinal; Collison, Kathryn; Sharma, Raj Kumar

doi:10.1177/1479973118815692

Cited by 4 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed that the majority of children could correctly use the ELLIPTA DPI on their first attempt without caregiver assistance, and nearly all reported that they found it easy to use. This is consistent with ease‐of‐use studies of the ELLIPTA DPI conducted in adults with chronic obstructive pulmonary disease or asthma 7,12–16 . Our results are also comparable to the findings of other pediatric studies of inhaler use 3–5 that have shown correct training by study staff, together with caregiver supervision, is likely to help decrease handling errors.…”

Section: Discussionsupporting

confidence: 90%

“…This is consistent with ease-of-use studies of the ELLIPTA DPI conducted in adults with chronic obstructive pulmonary disease or asthma. 7,[12][13][14][15][16] Our results are also comparable to the findings of other pediatric studies of inhaler use 3-5 that have shown correct training by study staff, together with caregiver supervision, is likely to help decrease handling errors. In a similar manner, studies in adults have demonstrated that patients can benefit from training by HCPs.…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

The evaluation of the correct use and ease‐of use of the ELLIPTA DPI in children with asthma

Halverson

Liem²,

Heyes

et al. 2020

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

Rationale Asthma studies show many children use inhalers incorrectly even after instruction. For two age groups of children with asthma, we determined the proportions who used the once‐daily ELLIPTA dry‐powder inhaler (DPI) correctly, and who found it easy to use. Methods This was a multicenter, single‐arm, stratified, open‐label, placebo study (NCT03478657). Children aged 5–7 and 8–11 years were trained in, and required to demonstrate, correct placebo ELLIPTA DPI use at their first clinic visit. The inhaler was used at home once daily for 28 ± 2 days. On returning to the clinic, children were randomized to an age‐appropriate, ease‐of‐use questionnaire that had been developed and validated previously, and which rated the inhaler as “easy” or “hard” to use. Following questionnaire completion, children were then asked to demonstrate correct inhaler use. Correct use and ease‐of use were assessed in each age group (co‐primary endpoints) and overall (secondary endpoints). Results Of 222 enrolled children, 221 completed the study. Among children aged 5–7 years, 92% (n = 81/88) demonstrated correct ELLIPTA use on their first attempt, compared with 93% (n = 124/133) aged 8–11 years. Of these children, 98% (5–7 years: n = 79/81; 8–11 years: n = 121/124) rated the inhaler easy to use. Overall, 93% (n = 205/221) demonstrated correct inhaler use on their first attempt, and 98% (n = 200/205) rated it easy to use. Conclusion ELLIPTA DPI was used correctly and easily by most children on their first attempt without additional training.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 87%

The evaluation of the correct use and ease‐of use of the ELLIPTA DPI in children with asthma

Halverson

Liem²,

Heyes

et al. 2020

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Characteristics of each of the studies included in the analysis are reported in Table 1 . All included studies (200301 [ 17 ], 201071 [ 18 ], 206215 [ 19 ], and 206901 [ 20 ]) evaluated correct use of the placebo ELLIPTA DPI and 2 of the 4 studies (200301 [ 17 ] and 201071 [ 18 ]) evaluated ease-of-use of the placebo ELLIPTA DPI. Three studies (200301 [ 17 ], 206215 [ 19 ] and 206901 [ 20 ]) were crossover studies using two different placebo inhalers in a randomized sequence; the placebo ELLIPTA DPI and a comparator placebo inhaler with which they had no recent experience.…”

Section: Resultsmentioning

confidence: 99%

“…Three studies (200301 [ 17 ], 206215 [ 19 ] and 206901 [ 20 ]) were crossover studies using two different placebo inhalers in a randomized sequence; the placebo ELLIPTA DPI and a comparator placebo inhaler with which they had no recent experience. Study 201071 [ 18 ] used the placebo ELLIPTA DPI only. Of the 2 studies that used an ease-of-use questionnaire, study 200301 [ 17 ] used 1 version, while patients in study 201071 [ 18 ] were randomized to receive version A or B; the only difference between the versions was that response options were in an alternative order.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Inhaler technique errors are common in chronic obstructive pulmonary disease (COPD) treatment, potentially leading to poor disease management. Our pooled analysis approach assessed correct use and ease-of-use of a placebo ELLIPTA dry-powder inhaler (DPI) in patients with COPD. Methods Adults with COPD from open-label/non-blinded studies evaluating a placebo ELLIPTA DPI and reporting outcomes of correct use (based on the ELLIPTA DPI patient information leaflet [PIL]) and/or ease-of-use were included. Correct use and ease-of use at study end were primary and secondary endpoints, respectively. Data from patients in the placebo ELLIPTA DPI arm of each study were pooled, and the intent-to-treat (ITT) population was used for all analyses. Results Four placebo ELLIPTA DPI studies, reporting correct use (n = 4) and ease-of-use (n = 2), were included in the analysis. The ITT population comprised 1232 patients (mean age 66.2 years). For the primary endpoint, 80.1% (n = 975/1217) of patients demonstrated correct use at study end (95% confidence interval [CI]: 77.8%–82.3%). For the secondary endpoint, 95.7% (n = 797/833) of patients rated placebo ELLIPTA DPI use “easy”/“very easy” at study end (95% CI: 94.1%–97.0%). Correct use and “easy”/“very easy” user ratings remained high across younger (40–64 years) and older (≥65 years) age groups. Conclusions Across age groups, most patients used the placebo ELLIPTA DPI correctly and rated it “easy”/“very easy” to use. Consistent with the Global Initiative for Chronic Obstructive Lung Disease 2021 report, our findings emphasize that proper training and clear instructions on PILs are important for optimal inhaler use.

show abstract

Repurposing vilanterol as a novel potential antifungal for Candida albicans: In-silico & in-vitro approach

Prakash

Kabir

2022

Medicine in Drug Discovery

View full text Add to dashboard Cite

Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease

Cited by 4 publications

References 28 publications

The evaluation of the correct use and ease‐of use of the ELLIPTA DPI in children with asthma

The evaluation of the correct use and ease‐of use of the ELLIPTA DPI in children with asthma

Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease

Repurposing vilanterol as a novel potential antifungal for Candida albicans: In-silico & in-vitro approach

Contact Info

Product

Resources

About